Kodiak Sciences Stock Has Surged Following Trial Results
The biotech firm saw its shares climb 600 percent annually after positive data from the Phase 3 DAYBREAK study.
Updated on Oct. 5, 2026 in Biotech
Live Poll
Is now a good time for you to invest in clinical-stage biotech stocks?
Kodiak Sciences shares rose significantly after experimental treatments Zenkuda and tabirafusp-ted met primary endpoints in the Phase 3 DAYBREAK study. The company stock closed at $94.45 on October 2, 2026, nearing its 52-week high of $104.
Why it matters
Positive clinical results for its wet age-related macular degeneration treatments have driven investor optimism despite recent net losses. The success of these candidates is critical for the firm as it moves toward regulatory filings.
Zenkuda demonstrated statistical significance against aflibercept with a p-value of 0.0007, while 54 percent of patients reached a six-month dosing interval at the one-year mark. These results were part of the DAYBREAK study delivered on September 28, 2026.
The players
Kodiak Sciences
A biotechnology company that develops novel therapeutics for the treatment of retinal diseases.
The details
Kodiak Sciences utilizes biopolymer conjugates and a treat-to-dryness dosing approach to manage wet age-related macular degeneration. The company reported a net loss of $65.6 million and earnings per share of -$1.05 in Q2 2026.
Timeline
Q2 2026: The company recorded a net loss of $65.6 million.
September 28, 2026: Phase 3 DAYBREAK study results were delivered.
October 2, 2026: Kodiak Sciences stock closed at $94.45.
Q4 2026: The company intends to file a biologics license application for Zenkuda.
December 2026: Phase 3 results for KSI-101 are expected.
The Big Picture
The results of the Phase 3 DAYBREAK study represent a significant milestone in the development of new treatments for wet age-related macular degeneration. This trial success marks a pivot point for the company as it shifts from experimental development toward seeking regulatory authorization.
For investors, the recent stock performance reflects market expectations ahead of upcoming regulatory filings and future drug trial readouts. The success of these therapies may eventually offer new treatment options for patients suffering from wet age-related macular degeneration.
The takeaway
The company continues to advance its pipeline despite reporting a net loss of $65.6 million in the second quarter of 2026. Analysts remain focused on the firm, with an average 12-month price target of $116.67 for the stock.
What happens next
Kodiak Sciences is scheduled to file a biologics license application for Zenkuda in the fourth quarter of 2026, followed by the expected release of Phase 3 results for KSI-101 in December 2026.
Further reading
Learn more about the latest industry trends in the Biotech section.
Source note: This article includes information reported by ABC Money.
Live Poll
Is now a good time for you to invest in clinical-stage biotech stocks?
